As deformation and exudation of granulomas in the brain could be lethal in patients with TBM, it is reasonable to consider multiple specific MMP inhibitors, including marimastat, batimasat, and cipemastat, or other specific MMPs antibodies, such as an anti-MMP-9 monoclonal antibody, as potential adjunctive therapies [138, 139]. This evidence concerns the gene MMP9 and meningeal tuberculosis.